AI-generated summary
The authors report a prospective study of targeted UVB 308 nm excimer laser therapy in 57 patients with localized, mild, therapy-resistant atopic dermatitis, with complete remission in nearly 85% and partial remission in 15% after 10 treatments over 6 to 8 weeks. A further 48 patients with other inflammatory skin conditions were treated, with higher remission rates reported only for alopecia areata and oral lichen ruber mucosae. The authors conclude the approach cannot be transferred to all inflammatory skin diseases.
- Who or what was studied
- 57 patients with localized, mild, therapy-resistant atopic dermatitis, plus 48 patients with other inflammatory dermatoses (lichen simplex chronicus, nodular prurigo, granuloma anulare, alopecia areata, lichen ruber planus)
- Wavelengths
- 308, 311 nm
- Limits stated in the abstract
- The abstract describes a single prospective study without a stated control group and does not report the certainty of the findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm, 311 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.